Cite
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
MLA
Ito, Takahiko, et al. “Primary Tumor Location as a Predictor of Survival in Patients with RAS Wild-Type Colorectal Cancer Who Receive Molecularly Targeted Drugs as First-Line Therapy: A Multicenter Real-World Observational Study by the Japanese Society for Cancer of the Colon and Rectum.” International Journal of Clinical Oncology, vol. 27, no. 9, Sept. 2022, pp. 1450–58. EBSCOhost, https://doi.org/10.1007/s10147-022-02208-7.
APA
Ito, T., Takashima, A., Yamazaki, K., Yukami, H., Uetake, H., Tsuda, M., Suto, T., Moriwaki, T., Sugimoto, N., Ojima, H., Takii, Y., Yasui, H., Esaki, T., Tsuji, A., Goto, M., Saruta, M., Otsu, S., Shinozaki, K., Fujiwara, T., & Tamura, T. (2022). Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. International Journal of Clinical Oncology, 27(9), 1450–1458. https://doi.org/10.1007/s10147-022-02208-7
Chicago
Ito, Takahiko, Atsuo Takashima, Kentaro Yamazaki, Hiroki Yukami, Hiroyuki Uetake, Masahiro Tsuda, Takeshi Suto, et al. 2022. “Primary Tumor Location as a Predictor of Survival in Patients with RAS Wild-Type Colorectal Cancer Who Receive Molecularly Targeted Drugs as First-Line Therapy: A Multicenter Real-World Observational Study by the Japanese Society for Cancer of the Colon and Rectum.” International Journal of Clinical Oncology 27 (9): 1450–58. doi:10.1007/s10147-022-02208-7.